Aim: Human chorionic gonadotropin (hCG) is used frequently for luteal support in fresh in vitro fertilization cycles as it induces progesterone secretion from the ovaries after oocyte retrieval and modulates the endometrium for implantation in fresh cycles.
| INTRODUCTION
Luteal phase support is routinely administered worldwide to women undergoing in vitro fertilization (IVF) treatment. 1 Luteal support is associated with a significantly higher pregnancy rate, compared with the pregnancy rates with no support. 2 The most commonly used types of supplementation include progesterone and/or human chorionic gonadotropin (hCG). 1 It is still unclear whether progesterone alone, hCG alone, or a combination of both will provide the optimal degree of support. 1 It has been reported that hCG supplementation results in higher pregnancy rates 2 and live birth rates, 3 compared to progesterone supplementation. In another prospective randomized study, in which i.m. hCG was compared with i.m. progesterone, luteal phase supplementation with hCG resulted in better conception rates, 4 while other studies reported that hCG administration as a form of luteal supplementation did not have significant benefits in comparison with progesterone supplementation. 5, 6 The administration of hCG leads to an increased production of estradiol and progesterone by the corpus luteum. 7 In addition to its classical endocrine role, a series of studies has shown that hCG exerts paracrine effects in the uterine environment. 8, 9 It has been reported that stimulating leukemia inhibitory factor (LIF) production by hCG is concentration-dependent, suggesting that the blastocyst might influence its own implantation through hCG. 8 It also has been reported that the specific interaction of blastocyst-derived hCG and the endometrial luteinizing hormone (LH) and hCG receptors constitutes a fundamental component of the molecular dialogue at the materno-fetal interface. 9 Although the controversy that has been raised regarding the expression of the LH and hCG receptors in the human endometrium remains, 10 several studies have shown that the LH and hCG receptors are present in the human endometrium. 11, 12 In consideration of these reports, it seems that hCG that is used in luteal support might have a direct effect on the endometrium at implantation. However, hCG is not usually used for the transfer of cryopreserved-thawed embryos with estrogen/progesterone replacement cycles because ovulation is suppressed, there is no corpus luteum formation, and no luteotropic effect is expected. In order to study the direct effect of hCG on the endometrium at implantation, this study evaluated whether hCG supplementation would be beneficial for cryopreserved-thawed embryo transfer with estrogen/ progesterone replacement cycles.
| MATERIALS AND METHODS
This prospective randomized study was done at a private IVF/intra- 
| RESULTS
There was no significant difference between groups 1 and 2 in the levels of serum estradiol and progesterone on day 23. 
| DISCUSSION
This is the first report to evaluate whether i.m. hCG supplementation is beneficial for cryopreserved-thawed embryo transfers with HR cycles.
The results indicate that i.m. hCG supplementation is not beneficial for frozen-thawed embryo transfers with HR cycles. In this study, i.m.
hCG injection, rather than intrauterine hCG injection or supplements of hCG that are added to the culture media, was used because the i.m.
injection is the only method that has been approved by the Japanese Ministry of Health, Labour, and Welfare. As the half-life of hCG is 24 hours, the administration of hCG three times, on days 17, 20, and 23, was expected to provide longer term benefits, as compared to a single intrauterine injection. Human chorionic gonadotropin is known to have an endocrine role as a luteotropic hormone that is responsible for the maintenance of progesterone production by the maternal corpus luteum. A series of studies has shown that hCG exerts paracrine effects in the uterine environment. 8, 9 In fact, it has been shown that hCG administration during the secretory phase significantly modulates several endometrial paracrine parameters that are correlative with endometrial differentiation (eg, insulin-like growth factor-binding protein 1), angiogenesis (eg, vascular endothelial growth factor), implantation (eg, LIF, macrophage colony stimulating factor), and tissue remodeling (eg, matrix metallopeptidase 9). 14 Several studies have shown that the LH and hCG receptors are present in the human endometrium. 11, 12 Furthermore, hCG has been detected at various levels in blastocyst culture media. 15, 16 The expression of hCG has been documented as beginning at 2 days after fertilization. 17 Therefore, it is likely that the specific interaction of blastocyst-derived hCG and the endometrial LH and hCG receptors constitutes a fundamental component of the molecular dialogue at the materno-fetal interface. 9 However, this study's results did not show the efficacy of hCG supplementation in frozenthawed embryo transfers with HR cycles. The results might indicate that the amount of hCG that is expressed by the embryo itself at the local implantation site is sufficient to support the molecular dialogue at the materno-fetal interface. Alternatively, hCG itself does not have any role in the molecular dialogue at the materno-fetal interface. In order to determine the role of hCG in the molecular dialogue at the materno-fetal interface, further investigations will be required. 
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